Tech Company Financing Transactions
Loxo Oncology Funding Round
Aisling Capital and OrbiMed invested in a $33 million Series A funding round for Loxo Oncology. The round was announced on 10/4/2013.
Transaction Overview
Company Name
Announced On
10/4/2013
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series A
Investors
Aisling Capital (Dov Goldstein)
OrbiMed (David Bonita)
Proceeds Purpose
This funding allows us to advance our pipeline on multiple fronts.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
281 Tresser Blvd. 9th Floor
Stamford, CT 06901
USA
Stamford, CT 06901
USA
Phone
Website
Email Address
Overview
Loxo Oncology was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Josh Bilenker
Chief Medical Officer
Nora Ku
Vice President
Christopher Pierce
VP - Bus. Development
Jacob Naarden
VP - Bus. Development
Nisha Nanda
VP - Finance
Jennifer Burstein
VP - Human Resources
Jennifer Kronick
VP - Operations
Sara Slifka
VP - R & D
Michael Rothenberg
VP - Regulatory Affairs
Deborah Morosini
Browse more venture capital transactions:
Prev: 10/4/2013: MongoDB venture capital transaction
Next: 10/7/2013: Lark Health venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs